Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Tonix Pharma ( (TNXP) ) has provided an announcement.
Tonix Pharmaceuticals has appointed Gary Ainsworth as Vice President of Market Access, signaling potential strategic shifts in market positioning. The company also announced the expected timelines for topline data from its TNX-1300 Phase 2 study for cocaine intoxication and TNX-1500 Phase 1 study for kidney transplant rejection, marking significant steps in their product development pipeline.
More about Tonix Pharma
Tonix Pharmaceuticals Holding Corp. operates in the pharmaceutical industry, focusing on the development of innovative therapies. Its primary products include TNX-1300 for cocaine intoxication and TNX-1500 for the prevention of kidney transplant rejection, with a market focus on addressing critical unmet medical needs.
YTD Price Performance: -7.10%
Average Trading Volume: 102,751,987
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $58.4M
Learn more about TNXP stock on TipRanks’ Stock Analysis page.